🟢 GRAIL is trading 5% up today after FDA plans September Galleri advisory meeting

GRAIL is trading 5.47% up now at $66.87 after the FDA announced plans for a September advisory committee meeting on Galleri, its multi-cancer screening test.

• Reuters reported the announcement sent shares up 4% in morning trading.
• The panel will review GRAIL’s premarket approval request, creating a significant regulatory catalyst, though the FDA is not required to follow its recommendation.
• Second-quarter revenue reached $44.7 million, with 35% Galleri test-volume growth; investors remain focused on the approval timeline.